E-viri
PDF
Recenzirano
Odprti dostop
-
Vaduganathan, Muthiah; Sathiyakumar, Vasanth; Singh, Avinainder; McCarthy, Cian P.; Qamar, Arman; Januzzi, James L.; Scirica, Benjamin M.; Butler, Javed; Cannon, Christopher P.; Bhatt, Deepak L.
Journal of the American College of Cardiology, 12/2018, Letnik: 72, Številka: 25Journal Article
Empagliflozin was shown to reduce risk of cardiovascular death among high-risk patients with type 2 diabetes mellitus (1), which led to the U.S. Food and Drug Administration (FDA) expanding its labeling in December 2016 for reducing cardiovascular risk. ...we sought to determine specialty-specific prescriber trends of SGLT2i in a large U.S. tertiary care system over the last 5 years. ...these data from an integrated tertiary care system may not be generalizable to all settings.
